Last reviewed · How we verify
SOC 4F-PCC — Competitive Intelligence Brief
phase 3
PAR-1 antagonist
PAR-1 (Protease-Activated Receptor 1)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
SOC 4F-PCC (SOC 4F-PCC) — Takeda. SOC 4F-PCC is a Factor IIa protease-activated receptor 1 (PAR-1) antagonist that inhibits thrombin signaling to reduce thrombotic events.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SOC 4F-PCC TARGET | SOC 4F-PCC | Takeda | phase 3 | PAR-1 antagonist | PAR-1 (Protease-Activated Receptor 1) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (PAR-1 antagonist class)
- Takeda · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SOC 4F-PCC CI watch — RSS
- SOC 4F-PCC CI watch — Atom
- SOC 4F-PCC CI watch — JSON
- SOC 4F-PCC alone — RSS
- Whole PAR-1 antagonist class — RSS
Cite this brief
Drug Landscape (2026). SOC 4F-PCC — Competitive Intelligence Brief. https://druglandscape.com/ci/soc-4f-pcc. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab